Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have signed a consent form to participate in the study
- People who have been diagnosed with a specific type of blood cancer called Ph-negative acute lymphoblastic leukaemia (ALL) and have not yet received any treatment for it
Who may not be able to join:
- People whose ALL is of a type called "mature B" (based on specific cell surface markers or certain chromosomal changes)
- People whose ALL is "Ph-positive" (meaning a specific chromosomal change called the Philadelphia chromosome is present)
- People diagnosed with a type of acute leukaemia that does not fit clearly into one category (sometimes called undifferentiated or mixed)
- People with a history of heart problems involving the coronary arteries, heart valves, or high blood pressure-related heart disease that would make a certain class of chemotherapy (anthracyclines) unsafe to use
- People with active chronic liver disease, or whose bilirubin or liver enzyme levels are significantly elevated for reasons unrelated to their leukaemia
- People with severe long-term breathing difficulties
- People with kidney problems or elevated creatinine levels (a marker of kidney function) that are unrelated to their leukaemia
- People with serious neurological (brain or nerve) conditions unrelated to their leukaemia
- People whose overall physical condition is significantly affected (rated as grade 3 or 4 on a standard medical scale) for reasons other than their leukaemia
- People with uncontrolled infections including HIV, HTLV-1, hepatitis B, or hepatitis C
- People whose treating doctor determines they are not a suitable candidate for this treatment
- Pregnant women will require review by a multidisciplinary medical team and an ethics committee before eligibility can be determined (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Maria Moirano, Dr., Grupo Argentino de Tratamiento de la Leucemia Aguda
Phone: 541148771000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Evaluate event free survival of AYA Ph-negative ALL patients treating in first line depending on risk category.; Evaluate overall survival of AYA Ph-negative ALL patients treating in first line depending on risk category.; Evaluate toxicities of AYA Ph-negative ALL patients treating in first line depending on risk category.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.